FDA Expands ADMA's IVIG Label to Include Pediatric Patients With Primary Immunodeficiency
May 6th 2026The FDA has expanded ADMA Biologics’ intravenous immunoglobulin (IVIG) therapy label to include pediatric patients aged 2 years and older with primary humoral immunodeficiency, allowing earlier treatment access to help prevent serious infections in children with this rare immune disorder
Is Hantavirus Human-To-Human Transmissible?
May 6th 2026Hantavirus is primarily spread from rodents to humans and is not generally considered human-to-human transmissible, though rare concern is being raised about specific strains like the Andes variant that may allow limited transmission under close contact, prompting pharmacists to focus on risk assessment, prevention, and patient education.